The $192 Million Bet on a Sleep Apnea Pill: A New Era for Sleep Medicine? Apnimed, a Cambridge based biotech, has raised $192 million in its initial public offering, valuing the company at over $600 million.
This significant investment is a testament to the startup's ambitious goal of revolutionizing sleep apnea treatment with a once nightly pill.
The current standard care for sleep apnea – continuous positive airway pressure (CPAP) machines – can be cumbersome and often met with resistance by patients.